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Abstract
Background: Stroke/thromboembolic events, infections, and death are all significantly
increased by antipsychotics in dementia but little is known about why they can be
harmful. Using anovel applicationof a drug repurposing paradigm,weaimed to identify
potential mechanisms underlying adverse events.
Methods:Whole transcriptome signatures were generated for SH-SY5Y cells treated
with amisulpride, risperidone, and volinanserin using RNA sequencing. Bioinformatic
analysis was performed that scored the association between antipsychotic signatures
and expression data from 415,252 samples in the National Center for Biotechnology
Information Gene ExpressionOmnibus (NCBI GEO) repository.
Results:Atherosclerosis, venous thromboembolism, and influenza NCBI GEO-derived
samples scored positively against antipsychotic signatures. Pathways enriched in
antipsychotic signatures were linked to the cardiovascular and immune systems (eg,
brain derived neurotrophic factor [BDNF], platelet derived growth factor receptor
[PDGFR]-beta, tumor necrosis factor [TNF], transforming growth factor [TGF]-beta,
selenoamino acid metabolism, and influenza infection).
Conclusions: These findings for the first time mechanistically link antipsychotics to
specific cardiovascular and infectious diseases which are known side effects of their
use in dementia, providing new information to explain related adverse events.
KEYWORDS
amisulpride, antipsychotic, brain derived neurotrophic factor, cardiovascular, immune, platelet
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1 BACKGROUND
Atypical antipsychotics are a commonly used off-label treatment for
agitation, aggression, and psychosis in dementia. They are modestly
effective but have a severe side effect profile which includes sedation,
thromboembolic events, QTc prolongation, falls, fractures, infections,
stroke, and all-causemortality.1,2 The narrowmargin of clinical benefit
and the lack of alternative pharmacological agentsmakes investigation
of drug safety a key priority. Antipsychotic therapeutic mechanism
of action (MoA) is primarily via antagonism of serotonin receptor 2A
(5-HT2A) and/or dopamine receptors 2 and 3 (D2/3) but many also
have significant antihistaminergic, anticholinergic, and antiadren-
ergic properties. It has long been hypothesized that this off-target
activity is a contributor to the side effect profile of antipsychotics in
dementia.1,3–6 It has also been suggested that generic mechanisms
such as over-sedation leading to dehydration, failure to clear the
chest, and inactivity may be key mediating mechanisms.1 Therefore,
an important unanswered question is whether side effects are a
primary result of perturbations to specific biological processes (eg,
cardiovascular biology, immune response) or secondary consequences
of more general mechanisms like sedation. Understanding the answer
to this question will help enormously in the future development
of safer antipsychotics and inform the safer prescribing of existing
agents.
High-throughput in silico screening approaches leveraging gene
expression datamay provide novel mechanistic insights into dementia-
related side effects. Such approaches rest on the principle that tran-
scriptional activity represents a useful surrogate for disease states
and are widely used to triage compounds in drug repurposing stud-
ies (exemplified by the Connectivity Map, Cmap).7–11 A typical appli-
cation would see a gene expression signature from a candidate dis-
ease screened against a compound expression database, with neg-
ative scores indicating possible therapeutic benefits (ie, evidence
that the drug reverses the disease transcriptional signature). It fol-
lows that a positive score between a given compound and a con-
dition that is a side effect of that compound would indicate a
MoA which is linked to the condition. Thus, a key advantage of
this approach in the examination of drug side effects is a more
direct biological link to human disease side effects without testing in
humans.
In the present study, our aim was to determine whether tran-
scriptional perturbations derived in vitro could elucidate mechanisms
underlying adverse effects of antipsychotic use in dementia. We gen-
erated gene expression signatures for three antipsychotics represent-
ing a range of mechanisms of action relevant to the current landscape
of drug development and clinical use in dementia: amisulpride (primar-
ily a D2/D3 antagonist), risperidone (primarily a 5HT2A/D2 antago-
nist), and volinanserin (highly selective 5HT2A inverse agonist).12–14
We then used a high-throughput bioinformatic scoring algorithm to
test for association with human diseases. Specifically, we hypothe-
sized that the antipsychotic signatures would score positively with
conditions and diseases related to known side effects of their use in
dementia.
RESEARCH INCONTEXT
1. Systematic review: The authors reviewed the litera-
ture and the landscape of current drug development
for neuropsychiatric symptoms in dementia using online
searches and conference presentations. Antipsychotics
are still commonly prescribed off label and are associ-
ated with a number of severe side effects in dementia.
Many newer drugs are refinements of existing antipsy-
choticmechanisms of action but little is known about spe-
cific mechanisms underlying harm.
2. Interpretation: Our findings link antipsychotics to cardio-
vascular and infectious disease, suggesting that adverse
effects of their use in dementia may be mediated by spe-
cific mechanisms as well as secondary to more general
effects like sedation.
3. Future directions: These findings provide a collec-
tion of candidate adverse effect mechanisms. Future
research should extend these to biological models of
aging and frailty, epidemiological studies, and should
explore the possibility of our approach in discovering
new adverse events related to antipsychotics to improve
safety screening in the drug development pipeline.
2 MATERIALS AND METHODS
2.1 Antipsychotics
The following antipsychotic concentrations were used, based on pre-
viously published doses:12,14–17 1 μM amisulpride (catalogue number
CAY14619, CambridgeBioscience, UK), 100nMrisperidone (catalogue
number ab120393, Abcam, UK), and 10 nM volinanserin (catalogue
number CAY15936). Dimehtyl sulfoxide (DMSO) was used as the vehi-
cle for all compounds.
2.2 Cell culture
SH-SY5Y human neuroblastoma cells (P13) were cultured in media
(DMEM/F-12, GlutaMAX Supplement; catalogue number 11514436,
Fisher Scientific, UK) containing filtered10% fetal bovine serum (Gibco
Fetal Bovine Serum, heat inactivated; catalogue number 11550356).
Cells were maintained at 37◦C, 5% CO2, and atmospheric O2 in a
humidified incubator.Cellswere seededat adensityof≈70% in six-well
plates the day before experimentation and grown in the same media.
On the day of the experiment, cells were treated with filter sterilized
media containing the antipsychotic compounds or vehicle at desired
concentration for 24 hours. No cell death was observed at the drug
doses tested. Four individual culture well replicates were collected for
each compound and vehicle.
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2.3 RNA extraction
To preserve RNA in SH-SY5Y cells, media was removed and 500 μl
of Trizol (Invitrogen Trizol reagent; catalogue number 15596026) was
applied to each well. Cells were mixed thoroughly with the reagent
and collected for RNA extraction. RNA was purified using an RNA kit
(Direct-zol RNA MiniPrep w/ Zymo-Spin IIC Columns [Capped]; cata-
logue number R2052) as shown in the instruction manual and stored
at –80◦C. After RNA purification, the concentration of RNA was mea-
sured by Qubit 3.0 Fluorometer using Qubit high sensitivity RNA kit
(Qubit RNA HS Assay Kit; catalogue number Q32852, ThermoFisher
Scientific, UK). The quality of purified RNA was tested using Agilent
2200 TapeStation system and RNA ScreenTape Assay (RNA Screen-
Tape; catalogue number 5067-5576, RNA ScreenTape Sample Buffer;
catalogue number 5067-5577, Agilent, UK). The mean RNA Integrity
Number (RIN, an indicator of RNA quality ranging from 1 to 10) value
across all samples was 9.87 (minimum: 9.6, maximum: 10). RNA sam-
ples were diluted at the desired concentration for polyA-tail library
preparation and sequencing.
2.4 RNA sequencing
Illumina HiSeq 2500 standard mode sequencing system was used to
sequence RNA samples (poly-A tail library preparation, 125bp paired
end, 20 million reads per sample). Quality control using FastQC was
performed to remove low-quality reads. To compare the expression
profile of samples, STAR (version 2.6.1a) was used to align the RNA
reads to the reference human genome (hg38). To create and sort bam
files, samtools (version 0.1.16) and to index and assignmapped reads to
genomic features, featureCounts (version 1.6.1) was used.
2.5 Identification of differentially expression
genes
To generate differentially expressed genes (DEGs), DESeq2 (version
1.16.1) was applied to read counts from each compound versus con-
trol (n = 4 for each group), identifying significant changes based on a
negative binomial distribution. Statistical filtering based on the log2
of 1.5-fold change and a false discovery rate adjusted P-value (PFDR)
<.05 were used to generate the gene lists used in subsequent analysis.
A 1.5-fold change cut-off was applied so that genes perturbed due to
off target (whichmay be relevant to side effects) as well as therapeutic
actions of the compounds were captured.
2.6 High-throughput screening of antipsychotic
drug signatures against dementia-related side effects
To establish whether antipsychotic gene expression signatures were
associatedwith geneexpressionof conditions representing known side
effects, we first conducted a high-throughput in silico screen against
gene expression data from 415,252 human samples from 11,305
experimental series in the National Center for Biotechnology Infor-
mation Gene Expression Omnibus (NCBI GEO) repository using the
Searchable Platform Independent Expression Database (SPIED, www.
spied.org.uk).18,19 The SPIED tool facilitates querying of publicly avail-
able gene expression data from NCBI GEO with user-defined tran-
scriptional signatures.8,9,11 A major barrier to high-throughput in sil-
ico interrogation of human disease gene expression samples is that in
many NCBI GEO series the case/control assignment of individual sam-
ples is not clear without manually curating the data (thus it is not prac-
tical to determine relative expression change acrossmany hundreds or
thousands of series). SPIED overcomes this by calculating an effective
fold (EF) change at each probe in a sample, defined as the expression
level of each individual array probe relative to the experimental series
average.19
In SPIED, association testing between the query antipsychotic sig-
natures and NCBI GEO sample data are done via a Fisher exact test
on 2 × 2 contingency table of up- and downregulated genes. A score is
assigned to each sample to reflect the relationship with antipsychotic
expression. This score is defined as the sum of the number of genes
perturbed in the same direction subtracted from the sum of number of
genes perturbed in the opposite direction, divided by the total number
of genes common to antipsychotic and sample profiles. Possible scores
therefore range between –1 (all genes perturbed in the opposite direc-
tion) and 1 (all genes perturbed in the same direction), thus quantifying
the relationship between an individual sample and query signature. If
an NCBI disease series is associated with an antipsychotic then by def-
inition individual samples within that series will positively score with
the drug. This initial screen thus provides a first indication of associa-
tion, which can then be followed up. Specifically, highly scoring samples
from NCBI GEO series assaying diseases or conditions of interest can
then be manually assigned case/control status and tested for enrich-
ment of positive scores among cases relative to controls. Thus, using
SPIED, we followed the workflow described in detail inWilliams19 and
broadly comprising the following stages (graphically summarized in
Figure 1):
1. Generate a statistically filtered list of DEGs for each antipsychotic
(described in Section 2.4).
2. Use SPIED to screen each antipsychotic signature against all human
gene expression micro-array data in the NCBI GEO repository.
The resulting SPIED output is a "longlist" of the 500 top scoring
NCBI GEO samples with a statistically significant (adjusted P-value
.05/11,305 NCBI GEO series = P < 4.42 × 10−6) score (either pos-
itive or negative). The list was then manually curated to shortlist
samples fromNCBI GEO series meeting the following criteria:
∙ Sample is from a series assaying one of the following disease
areas relevant to side effects of antipsychotic use in dementia:
thromboembolic events, stroke, bone density/osteoporosis (rel-
evant to fractures), pneumonia and other respiratory infections,
urinary tract infections, and atherosclerosis/coronary artery dis-
ease.
∙ Case/control design.
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F IGURE 1 Graphical representation of the Searchable Platform Independent Expression Database (SPIED) screeningmethod
3. Manually annotate every sample in each shortlisted series as case
or control according to their designation in NCBI GEO.
4. Test for enrichment of positive scores among cases relative to
controls in each series using Fisher test. Given the correlation
between the three antipsychotic signatures, a Bonferroni correc-
tion of 0.05/N shortlisted series was applied.
3 RESULTS
3.1 Differentially expressed genes
In total, 10,841 genes were detected and used for differential gene
expression analysis. Gene expression level and bidirectional distribu-
tion pattern of expression associated with each antipsychotic is illus-
trated in the volcano plots presented in Figure 2. Treatment of cells
with volinanserin, amisulpride, and risperidone resulted in the activa-
tion of 2267 (1749 downregulated and 518 upregulated), 1026 (922
downregulated and 104 upregulated) and 809 (756 downregulated
and 53 upregulated) genes, respectively (Figure 2, a full list of differen-
tially expressed gene names and statistics is shown in Tables S1–S3 in
supporting information). The three antipsychotic signatures were pos-
itively correlated with each other (amisulpride vs risperidone, Spear-
man test: rs = 0.76, amisulpride vs volinanserin: rs = 0.88, risperidone
vs volinanserin: rs = 0.66). Raw sequence data are available in the GEO
repository under GSE149611.
3.2 Association between antipsychotic and
dementia-related side effects
Each antipsychotic signature was screened against the NCBI GEO
repository using SPIED (Step 2, Figure 1). As this is a high-throughput
screen, we focused on the top 500 statistically significant (Bonfer-
roni adjusted P-value .05/11,305 NCBI GEO series: P < 4.42 × 10−6)
scoring samples identified by SPIED for each drug. Of the 1500 total
antipsychotic-sample scores identified by SPIED, 817 were statisti-
cally significantly associated with at least two antipsychotics, leaving
683 unique samples in the long list. This list of samples along with
associated scores, P-value, and number of overlapping genes is shown
in Table S4 in supporting information. Of these 683 unique samples,
18 were from series which assayed diseases/conditions relevant to
side effects of antipsychotics in dementia (Step 3, Figure 1). Twelve
of these were excluded as they were not case-control designs (mean-
ing testing for association between the score in individual samples
and case/control status is not possible). Thus, six series were taken
forward for further analysis: GSE13850 and GSE2208 (bone density),
GSE23746 (atherosclerosis), GSE19151 (venous thromboembolism
[VTE]), GSE7638 (coronary artery disease [CAD]), GSE17156 (respira-
tory infection, containing three conditions: influenza, rhinovirus, and
respiratory syncytial virus,whichwere analyzed separately in this anal-
ysis). Individual sample-level data showing the distributions of cases
and controls in each series and their associated scores and P-values are
shown in Tables S5 to S27 in supporting information (Step 4, Figure 1).
Table 1 shows that atherosclerosis cases (GSE23746)were enriched
for positive scores for all three antipsychotics (Fisher exact test
amisulpride, P = .002; risperidone, P = 6.98 × 10−5; volinanserin,
P = 5.5 × 10−3). VTE cases (GSE19151) were enriched for positive
scores for risperidone (P = 8.13 × 10−7) and volinanserin (P = .002).
Finally, influenza cases (GSE7638)wereenriched for positive scores for
amisulpride (P= .002).
3.2.1 Pathway analysis
Pathway analysis was then performed to elucidate more specific bio-
logical mechanisms underlying the reported associations. As this study
is focused on side effects rather than therapeutic action, a pruned
gene list for each antipsychotic was created; this comprised only genes
which were also differentially expressed in cases relative to controls in
the series in Table 1. Thus, the first step was to create a list of DEGs for
atherosclerosis, VTE, and influenza. Thiswas done using theNCBIGEO
analyzer tool using a PFDR < .05 threshold (gene lists for each signature
are shown in Tables S28 to S30). DEGs in each antipsychotic signature
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F IGURE 2 Volcano plots illustrating differentially expressed genes for amisulpride, risperidone, and volinanserin versus dimehtyl sulfoxide
(DMSO). Dotted horizontal lines mark adjusted P-value threshold of .05; dotted vertical lines mark log 1.5-fold change threshold. Greenmarkers
indicate statistically significantly differentially expressed genes with>±1.5-fold change
which were not also present in any of the side effects signatures were
excluded, creating three pruned gene lists.
For amisulpride, risperidone, and volinanserin, query lists for path-
way analysis comprised 547, 435, and 1218 genes, respectively (ie,
those genes overlapping with atherosclerosis, VTE, or influenza).
Genes in each of these three pruned antipsychotic lists were ranked in
descending order by the log-fold change associated with the antipsy-
chotic and tested for enrichment using the g:Profiler tool, which is
well suited to pruned lists.20 Gene set enrichment analyses included
the following gene ontology (GO) and biological pathway sources: GO
molecular function (MF), GO cellular components (CC), GO biological
processes (BP), Kyoto Encyclopedia of Genes and Genomes (KEGG),
Reactome, and WikiPathways. Any annotations not curated manually
(therefore being less reliable) were excluded. g:Profiler’s multiple test-
ing correction was applied (known as "g:SCS" and developed specifi-
cally for pathway analysis). A g:SCS-adjusted P-value threshold of 0.05
was used.21 Outputs were filtered to exclude pathway gene sets with
<10 or>200 genes andwith<3 overlapping genes in the input list.
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F IGURE 3 Plot of gene ontology (GO) terms and pathways statistically significantly enriched in amisulpride, risperidone, and volinanserin.
Abbreviations: BP, biological processes; CC, cellular component; MF, molecular function; KEGG, Kyoto Encyclopedia of Genes and Genomes;
REAC, Reactome;WP,WikiPathways; NMD, nonsense-mediated decay; ER, endoplasmic reticulum;MAPK, mitogen-activated protein kinase; EJC,
exon junction complex; GTP, guanosine-5’-triphosphate; ROS, reactive oxygen species; TNF, tumor necrosis factor; RAF, rapidly accelerated
fibrosarcoma; TGF, transforming growth factor; TSH, thyroid stimulating hormone; PDGFR, platelet derived growth factor receptor; BDNF,
brain-derived neurotrophic factor
3.2.2 Biological pathways
Genes from 39, 23, and 44 GO terms and pathways were enriched in
amisulpride, risperidone, and volinanserin, respectively (Figure 3, with
detailed results in Table S31).
Twenty-three and 21 Reactome pathways were enriched in amisul-
pride andvolinanserin, respectively. Anumberof these related to infec-
tious disease pathways (eg, viral mRNA transcription: volinanserin,
g:SCS adjusted P = 6.75x−4, amisulpride P = .005; influenza life cycle:
amisulpride, P = .003, volinanserin, P = .009). Two pathways linked to
the essential amino acid selenium were also enriched in both amisul-
pride and volinanserin: selenocysteine synthesis (amisulpride,P= .003,
volinanserin, P= .009) and selenoamino acid metabolism (amisulpride,
P= .01, volinanserin, P= .03).
For risperidone, 14 pathways across the KEGG (n= 2), Reactome (n
= 3), and WikiPathways (n = 9) databases were identified. The Reac-
tome pathways were linked to MAPK (RAF-independent MAPK1/3
activation, P = .002; negative regulation of MAPK pathway, P =
.01). KEGG and WikiPathways enriched in risperidone were linked to
cell growth/differentiation, with some growth factor pathways linked
to the cardiovascular system and inflammation: brain derived neu-
rotrophic factor (BDNF) signaling pathway, P = .045; platelet derived
growth factor receptor (PDGFR)-beta signaling, P = .034; osteoclast
differentiation, P = .002; inflammation; oncostatin M signaling, P =
.0005; tumor necrosis factor (TNF) signaling pathway, P = .01; trans-
forming growth factor (TGF) beta signaling, P= 4.6x−4.
3.2.3 GO terms
All GO terms enriched in the three antipsychotic lists are shown in Fig-
ure 3, with detailed results in Table S31. Removing redundant terms
using Revigo22 showed that the amisulpride gene list was primarily
enriched for GO terms related to viral transcription (P = 1.29x−6), sig-
nal recognition particle (SRP)-dependent co-translational protein tar-
geting tomembrane (P=3.43E-05), cystolic ribosome (P=2.2x−5), and
structural constituent of ribosome (P= 1.29x−6).
Risperidone was enriched for terms relating to peptidyl-threonine
dephosphorylation (P = 8.43x−4), response to mechanical stimulus (P
= .02), positive regulation of pri-miRNA transcription from RNA poly-
merase II promotor (P = .03), RNA polymerase II transcription factor
complex (P= .01), MAP kinase phosphatase activity (P= 3.5x−5).
Volinanserinwas enriched for viral transcription (P= 6.94x−7), SRP-
dependent co-translational protein targeting tomembrane (P= 1.07E-
04), cystolic ribosome (P= 2.46x−5), and structural constituent of ribo-
some (P= 2.03x−6).
4 DISCUSSION
This study aimed to elucidate mechanisms underlying side effects
associated with antipsychotic use in dementia. To our knowledge we
provide the first evidence mechanistically linking antipsychotics with
specific cardiovascular and infectious diseases that are common side
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effects of their use in dementia. Supporting our hypothesis, the initial
high-throughput screen identified three conditions related to known
side effectswhichwere associatedwith the antipsychotics; atheroscle-
rosis cases were enriched for positive scores for all three antipsy-
chotics, VTE cases were enriched with positive scores for risperi-
done and volinanserin, and influenza cases were enriched with posi-
tive scores for amisulpride. Supplementing these drug–disease asso-
ciations, a number of biological pathways related to cardiovascular
biology, infectious disease, and inflammation/immune system were
enriched across antipsychotic signatures. These findings suggest spe-
cific cardiovascular and immune processes may underlie some harmful
effects of antipsychotics and for the first time provide a number of can-
didates which can now be prioritized for further investigation.
Notable pathways enriched in risperidone include BDNF, PDGFR-
beta, TNF, and TGF-beta signaling. Findings from previous in vitro
and in vivo studies strongly implicate PDGFR-beta in atherosclero-
sis and cardiovascular disease, providing a possible mechanism to
explain the positive association between the three antipsychotics and
atherosclerosis and VTE observed in this study.23 Similarly, BDNF also
plays a role in cardiovascular disease (as well as neuroplasticity and
development)24,25 and is expressed in a variety of blood cells, the heart,
and vasculature.26 It is also noteworthy that previous studies have
demonstrated that part of risperidone’s pro-cognitive therapeuticMoA
may be via BDNF.27 It is evident fromour findings thatmoreworkmust
be done to untangle this complex element of antipsychoticMoA,where
BDNF is plausibly related to both beneficial and detrimental effects
of antipsychotics, which is highly relevant to dementia in which the
margin between clinical benefit and harm is so narrow. Two pathways
linked to the essential amino acid selenium were enriched in amisul-
pride and volinanserin. Selenium plays a role in preventing oxidative
stress and has beenwidely linked in observational studies to cardiovas-
cular disease and atherosclerosis.28 Moreover, one study in patients
with schizophrenia implicated selenium deficiency in the adverse car-
diac effects of clozapine, though it was not clear whether the defi-
ciency was caused by the drug or the schizophrenia itself.29 Our find-
ings bring greater clarity to this previous work by providing evidence
that antipsychotics directly act on selenium pathways. This has partic-
ular relevance to neurodegeneration in which selenium deficiency in
AD brain tissue has been observed and is hypothesized to play a role
in cardiovascular side effects in Parkinson’s disease.30,31 Our findings
provide a clear indication for prioritizing study of selenium deficiency
and its interaction with antipsychotics in people with neurodegenera-
tive disease to understand if it may be a clinically useful marker.
Infectious disease and immune pathways were also enriched
across all three antipsychotics. These included a range of viral and
influenza-linked GO terms in amisulpride and volinanserin, and TNF
and TGF-beta in risperidone. Consistent with this, a recent study
showed a considerable global suppression of immune response in
mice treated with risperidone, indicated by reduction in a number of
cytokines during treatment.32 Our findings suggest that this impact
extends to other antipsychotics and so underscore the need to pri-
oritize investigation of immune response in people with dementia.
They also suggest that susceptibility to infection associated with
antipsychotics is not solely secondary to more general effects of
antipsychotics like sedation-induced inactivity or failure to clear the
chest.
Although more work needs to be done to build on the candidate
mechanisms highlighted in this study, their initial identification is an
important step which could ultimately have important implications for
clinical decisionmaking. For example, the incorporation ofmore formal
cardiovascular history screening, with a particular focus on thrombosis
risk or selenium deficiency, into clinical decision making could result in
greater harm reduction.
We note that there were differences in the overlapping side effect
profiles and pathways enriched between antipsychotics; however. it
would not be appropriate to draw direct comparison between them at
the specific pathway level or interpret differences as clinically relevant.
This is because these experiments were conducted in vitro, so cellular
responses will be affected by dosing and duration of exposure to each
compound; similarly, equivalent doses and bioavailability of drugs in
humans will differ. At a broader level however, it is worth noting that
associations between antipsychotics and side effects, and enrichment
of relevant biological pathways were observed across all compounds,
despite their differingMoAs. Further comparison in different biological
models, including those in which aging and frailty can be incorporated,
and epidemiological studies is now warranted.33 This line of investi-
gation could have important implications for AD, Parkinson’s disease,
and elderly people with schizophrenia for which clinical trials ofam-
isulpride and pimavanserin (a highly selective 5-HT2A inverse agonist)
have recently been published and more antipsychotic-like drugs are in
development.2,34–36
The overall trend toward downregulation of genes in this experi-
ment is also worth comment. This pattern was particularly notable in
risperidone, forwhich 53 geneswere upregulated and 756were down-
regulated. However, although notable this is not without precedent.
One study, with a similar design, which treated SK-N-SH neuroblas-
toma cell lines with risperidone for 24 hours showed 80% of genes
were downregulated in analysis of microarray data.12
With regard to limitations, the design and analysis of this study
follows the same principles as Cmap and therefore the same caveats
apply. These include the comparison between cell line–derived signa-
tures and human studies, specifically that it would be premature to
draw concrete conclusions on the clinical profile of compounds based
on these data alone. However, as with Cmap, the trade-off is an experi-
mental designwhich provides a high-throughput low-cost screen, anal-
ogous to a drug repurposing experiment inwhich thousands of licensed
compounds are triaged against a single disease signature. Similarly, in
this study, screening three antipsychotic signatures against thousands
of diseases showed that mechanisms underlying VTE, atherosclerosis,
and infection may be relevant to the side effect profiles of antipsy-
chotics, providing a clear rationale for prioritizing their investigation
in different biological models and epidemiological studies. In doing so,
this study also represents an important step toward safety screening
for compounds in development of neuropsychiatric symptoms in AD.
This study highlights molecular-level links between cardiovascular and
infectious diseases and antipsychotics, suggesting that adverse effects
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of their use in dementia may be mediated by specific mechanisms as
well as secondary to more general effects like sedation. These find-
ings provide a collectionof candidate adverse effectmechanismswhich
may have important implications for use of existing compounds in clin-
ical practice and the development of safer drugs for dementia in the
future.
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